Mark V. Roeder

mark.roeder@lw.com

+1.650.463.3043

Profile

Mark Roeder represents life sciences and technology companies at all stages of their life cycle, as well as the institutions that finance them. Mark advises companies on strategic transactions and corporate governance matters. Specifically, he counsels clients on:

Initial Public Offerings (IPOs)
Secondary and follow-on equity public offerings
Strategic buy-side and sell-side mergers and acquisitions
Venture capital financings
Convertible debt offerings

He also provides general company representation, advising executives and boards on topics such as:

Corporate governance matters
Fiduciary duties
Securities law compliance
Executive compensation matters
Shareholder activism and defense

Mark frequently speaks on the IPO process and corporate governance matters.

Experience

Mark's representative transactions include:

Life Sciences IPOs and Follow-on Equity Offerings – Company Representation

Ardelyx – US$60 million IPO and several follow-on equity offerings raising nearly US$350 million
Ascendis Pharma – US$124 million IPO and several follow-on equity public offerings raising more than US$900 million
CytomX Therapeutics – US$142 million follow-on equity public offering
Intermune –convertible notes offerings raising US$276 million, and several follow-on equity public offerings US$860 million
KYTHERA Biopharmaceuticals – US$80 million IPO and US$133 million follow-on offering
Mirna Therapeutics – US$49 million IPO
OncoMed Pharmaceuticals – US$87 million IPO and US$51 million follow-on equity public offering
Relypsa – US$78 million IPO and multiple follow-on equity public offerings raising nearly US$300 million
Revolution Medicines – US$230 million follow-on equity public offering
UNITY Biotechnology – US$85 million IPO

Life Sciences IPOs and Follow-on Equity Offerings – Underwriters Representation

Aduro Biotech – US$136 million IPO
Alios BioPharma – US$1.75 billion sale to Johnson & Johnson
AveXis – several follow-on equity public offerings raising nearly US$750 million
CytomX Therapeutics – US$92 million IPO

Life Sciences – M&A Transactions

CV Therapeutics – US$1.5 billion sale to Gilead Sciences following a successful defense against a hostile bid by Astellas Pharma
DVS Sciences – US$208 million sale to Fluidigm
Envoy Therapeutics – US$140 million sale to Takeda Pharmaceutical
KYTHERA Biopharmaceuticals – US$2.1 billion sale to Allergan
Menlo Therapeutics – US$120 million IPO
Modernizing Medicines – US$58 million acquisition of gMed
Odonate Therapeutics – US$160 million initial public
Pearl Therapeutics – US$1.15 billion sale to AstraZeneca
Relypsa – US$1.53 billion sale to Galenica Group

Technology IPOs and Follow-on Offerings – Company Representation

Integrated Device Technology – US$374 million convertible notes offering
Mellanox Technologies – US$117 million IPO and follow-on public equity offering raising nearly US$100 million

Technology – M&A Transactions

Greenplum – sale to EMC (confidential terms)
Integrated Device Technology – US$1.7 billion merger with Integrated Circuit Systems
Integrated Device Technology – US$7.1 billion sale to Reneasas
Mellanox Technologies – US$6.9 billion sale to Nvidia, US$811 million purchase of EZ Chip, US$82 million purchase of Kotura, US$218 million purchase of Voltaire, and US$48 million purchase of IPtronics
Netli – US$170 million sale to Akamai Technologies

Venture Financings

Lead Investors’ counsel in hundreds of venture financings, including investments in: Carta, Segment.io, Lucid Software, Duo Security, Mulesoft, Verkada, Cloudera, ROBLOX, Zulily, Tableau Software, and Box